Chris Seymour at $ONT.L Oxford @nanopore tweets about Apple Silicon's AMX instruction set. A mysterious set of instructions now beginning to be mapped out by a group of volunteer developers. So what does Apple Silicon mean for #Bioinformatics?
As many will know, $AAPL Apple came up with their own silicon a few years ago, a branch off the @ARM 64-bit designs, of which they've been diverging ever since. The Apple M1 and M2 cores have been thoroughly reviewed in social media, but less from the optics of #Bioinformatics.
First of all, what reason did @Apple have to design their own silicon? Could they not just have adopted an @ARM design and stick to it? Well, the history of the company is full of examples of Apple wanting to do "their own thing" rather than integrating someone else's silicon...
... in their own products. But this new endeavour of the Apple Silicon line of products is the boldest mode for Apple as a company: have their own silicon designs, book large chunks of TSMCs fab capacity to produce them, integrate the silicon tightly with their own software ...
... stack to fully optimize hardware and software together. And this software stack is what developers will use to compile their software against, including #Bioinformatics software developers.
The basic components of an Apple Silicon M1/M2 chip are (1) the standard ARMv8 capabilities, including the #SIMD#NEON vector instructions, plus (2) Apple's undocumented AMX instructions, then (3) The Neural Engine called ANE or NPU, and (4) The GPU (Metal Compute Shaders).
Because Apple cares about their own software stack, which Apple employees develop themselves, most of the blueprints on how to access the silicon are not well documented, or not at all in the public domain. That's the case for Apple's AMX1/AMX2 instructions.
So developers out there, including #Bioinformatics developers can decide to do this heavy lifting themselves either by (a) adopting the libraries that Apple themselves supports, or (b) use something like Rosetta2 or (c) wait for the OSS community to reverse engineer ...
... the instructions sets, implement them over the OSS software stack (Linux, LLVM, etc.) and bring the available OSS software stack to parity for Apple Silicon compared to where it currently is. Each approach has its pros and cons.
The Rosetta2 approach is the easiest, but also the least performant. Whereas relying on Apple's software stack can get tricky if there are unsupported layers, it can bring a performance boost compared to the Rosetta2 approach, e.g. in #Bioinformatics software.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
In #biotech#stocks news, no opening to the US market today due to Labor Day holiday, which is a perfect time to discuss the only stock in the list of #biotech companies that I track, which is not listed in the US stock market: $ONT.L Oxford @nanopore
ONT decided to IPO in the UK rather than the NASDAQ, with two main consequences to the stock price: (1) many of the retail broker apps with a US Dollar account won't trade it as easily as US stocks, and (2) the value of the stock will correlate with the value of GBP vs USD.
The later can be seen when looking at $ONT.L Oxford @nanopore stock versus the GBPUSD trend line (yellow): when the GBP loses value to the US Dollar, seemingly ONT loses value, being traded in GBP. And vice versa, for a large pharma company such as $AZN Astrazeneca ...
Another twitter profile of one of the #biotech#stocks that I track, this time it's $TWST TwistBio. The company is a DNA Write company, currently applying their tech to #SynthBio, #NGS and #AntibodyDiscovery
The different segments are easy to explain, and in many cases we can draw analogies to $ILMN Illumina in #NGS: they provide products and services to different segments as a 'tools' provider. Now on to Twist Biopharma, here is were things get complicated.
Twist Biopharma is by all intends an purposes just another branch that concentrates on the antibody side of things. Part of what they offer is just more 'products and services', like they would do with NGS or SynthBio. The complicated part is their intention to also engage...
In #biotech#stocks, another market opening, another tough readjustement of expectations for $NVTA Invitae at -7% opening.
The 5-day chart shows a seesawing pattern, with peaks coming from the 1-2 initial hours of market, which quickly deflate either within the day's trade value or the next day. As mentioned before in this twitter account, the shape of these can sometimes be indicative of a large...
... institutional fund loading up, submitting orders at a certain tick for a certain period of time, and adjusting the rate of buys to the response from the rest of the market. $NVTA Invitae's top institutional holders are well spread, with @ARKInvest on top at 12.5%
The field of #NGS is heating up and new contenders are now shipping their new instruments out there. MGI Tech is heading to both the US and the main European markets, whereas Element Bio, Singular and Ultima Genomics are starting in the US first, aiming at outside US the in 2023.
There are other companies with new tech out there that want to use to displace $ILMN Illumina's market share, including $PACB PacBio which is giving an update on their new tech in October, and $ONT.L Oxford @nanopore that has been shipping Kit14 for the last couple of months now.
$ILMN Illumina themselves are pencilled for their Chemistry X update, but for the noises they've made so far, it seems this will be a platform update, meaning the now 1000s of NovaSeqs and NextSeqs out there will need to be replaced. Think multi-year wave of stock update.
In #biotech#stocks news, $TXG @10xGenomics is opening upwards +4% in today's trading. The company is down more than 75% in the 52-wk window. They peaked in Q1 2021 and have since then declined at a similar pace as other $XBI stocks out there.
$TXG is in the #Singlecell and #Spatial biology field. They've recently made their pivot into Spatial Biology apparent, and have both an #NGS Next-Generation Sequencing and #InSitu imaging play on it, with their #Visium and #Xenium lines respectively.
The $TXG top institutional holders include Morgan Stanley with less than 10%, followed by 3 of the heavy hitters in #biotech: UK's Baillie Gifford, Vanguard Group, and Black Rock.
$EXAS Exact Sciences is one of the companies I track, in many ways a pioneer in the #LiquidBiopsy#CancerScreening field although with a low-tech method compared to other players in this field such as $ILMN Illumina (via @GrailBio), and what other companies are planning ...